Sumatriptan nasal spray 20 mg: Efficacy, tolerance and quality of life in migraine patients;Sumatriptan 20 mg administre par voie nasale: Efficacite, tolerance et qualite de vie des patients migraineux

Revue Neurologique

Volumn 156, Issue 6-7, 2000, Pages 646-653

  Geraud G ^a   Valette, C ^b  

^a CHU RANGUEIL   (France)

^b Laboratoire Glaxo Wellcome   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SUMATRIPTAN; SEROTONIN AGONIST; VASOCONSTRICTOR AGENT;

ADULT; AEROSOL; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; QUALITY OF LIFE; VOMITING; ADOLESCENT; CHEMICALLY INDUCED DISORDER; HOSPITALIZATION; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RECURRENT DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NAUSEA; QUALITY OF LIFE; QUESTIONNAIRES; RECURRENCE; SEROTONIN AGONISTS; SEVERITY OF ILLNESS INDEX; SUMATRIPTAN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 0042835059     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. ASGHARNE M, DEBUSSEY S. (1998). Tolerability of sumatriptan nasal spray in the acute treatment of migraine : a review of data from clinical trials. In: 40th Annual Scientific Meeting of the AASH, American Association for the Study of Headache, San Francisco, CA, United States, 26th-28th june 1998. Headache, 38:373.
2. ASHFORD E, SALONEN R, SAIERS J, WOESSNER M. (1998). Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. Cephalalgia, 18: 273-7.
3. BOUREAU F, CHAZOT G, EMILE J, BERTIN L, d'ALLENS H. French Sumatriptan Study Group (1995). Comparison of subcutaneous sumatriptan with usual acute treatments for Migraine. Eur Neurol, 35: 264-269.
4. DAHLÖF C, BOUCHARD J, CORTELLI P, HEYWOOD J, JANSEN JP, PHAM S, HIRSCH J, ADAMS J. And MILLER DW. (1997). A multinational investigation of the impact of subcutaneous sumatriptan - II : Health-related quality of life. PharmaEconomics, 11 (Suppl. 1): 24-34.
5. DAHLÖF CGH, DIMENÄS E. (1995). Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia, 15; 31-36.
6. DIAMOND S, ELKIND A, T JCKSON R, RYAN R, DEBUSSEY S, ASGHARNEJAD M. (1998). Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med, 7: 234-240.
7. GROSS MLP, DOWSON AJ, DEAVY L, DUTHIE T. (1996). Impact of oral sumatriptan 50mg on work productivity and quality of life in migraineurs. British Journal of Medical Economics, 10: 231-246.
8. Headache classification committee of the International Headache Society (1988). Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia, 8 (suppl.7): 1-96.
9. HENRY P, DURU G, CHAZOT G, DARTIGUES JF. et le GRIM (1993). La migraine en France. Étude épidémiologique, impact socio-économique et qualité de vie. John Libbey Eurotext, Paris, 138 p.
10. INSERM (FR) (1998). La Migraine : Connaissances descriptives, traitements et prévention. Paris : Les Éditions INSERM. 279 p.
11. JHINGRAN P, CADY RK, RUBINO J, MILLER D, GRICE RB and GUTTERMAN D.L. (1996). Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract, 42: 36-42.
12. LOFLAND JH, JOHNSON NE, BATENHORST AS, NASH DB. (1999). Changes in resource use and outcomes for patients with migraine treated with sumatriptan. Arch Intern Med, 159: 857-863.
13. MARKHAM A. (1998). Sumatriptan. Drugs, 55: 889-922.
14. MICHEL P, DARTIGUES JF, LINDOULSI A, HENRY P. (1997). Loss of productivity and quality of life in migraine sufferers among French workers: results from the GAZEL cohort. Headache, 37: 71-78.
15. MICHEL P, PARIENTE P, DURU G, DREYFUS JP, CHABRIAT H, HENRY P. (1996). Mig-Access: a population-based, nationwide, comparative survey of access to care in migraine in France. Cephalalgia, 16: 50-55.
16. OSTERHAUS JT, TOWNSEND RJ (1991). The quality of life of migraineurs: a cross-sectional profile. Cephalalgia, 11(suppl. 11) :103-104.
17. OSTERHAUS JT, TOWNSEND RJ, GANDEK ., WARE JE. (1994). Measuring the fonctional status and well-being of patients with migraine headache. Headache, 34: 337-343.
18. PEIKERT A, BECKERT WJ, ASHFORD EA, DAHLOF C, HASSANI H, SALONEN R. (1999). Sumatriptan nasal spray : a dose-ranging study in the acute treatment of migraine. Eur J Neurol, 6: 43-49.
19. PLOSKER GL and TAVISH D Mc (1994). Sumatriptan. Drugs, 47: 622-651.
20. RECHES A. (1995). The long-term tolerability, safety and efficacy of sumatriptan 20mg nasal spray in the acute treatment of migraine. In: Proceedings of the 7th International Headache Congres, Toronto, Canada. 16th-20th september 1995. Cephalalgia, 15 (suppl. 14); Poster.
21. RICHARD A, HENRY P, CHAZOT G, MASSIOU H, TISON S, MARCONNET R, CHICOYE A, d'Allens H. (1993). Qualité de vie et migraine. Validation du questionnaire QVM en consultation hospitalière et en médecine générale. Therapie, 48: 89-96.
22. RYAN R, ELKIND A, BAKER C, MULLICAN W, DEBUSSEY S and ASGHARNEJAD M. (1997). Sumatriptan nasal spray for the acute treatment of migraine - results of two clinical studies. Neurology, 49: 1225-1230.